Remus Pharmaceutical
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
June 23 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:
APPOINTS BHAVIK SHAH AS CHIEF FINANCIAL OFFICER EFFECTIVE JULY 09, 2026
Source text: ID:nNSE353CY2
Further company coverage: REMP.NS
(([email protected];))
June 23 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:
APPOINTS BHAVIK SHAH AS CHIEF FINANCIAL OFFICER EFFECTIVE JULY 09, 2026
Source text: ID:nNSE353CY2
Further company coverage: REMP.NS
(([email protected];))
June 22 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:
REMUS PHARMACEUTICALS - ANJALI SHAH RESIGNS AS CHIEF FINANCIAL OFFICER EFFECTIVE JULY 8, 2026
Source text: ID:nNSE30NzN4
Further company coverage: REMP.NS
(([email protected];))
June 22 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:
REMUS PHARMACEUTICALS - ANJALI SHAH RESIGNS AS CHIEF FINANCIAL OFFICER EFFECTIVE JULY 8, 2026
Source text: ID:nNSE30NzN4
Further company coverage: REMP.NS
(([email protected];))
Aug 29 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:
RE-APPOINTS ARPIT SHAH AS MANAGING DIRECTOR
Source text: ID:nNSEbXnMqX
Further company coverage: REMP.NS
(([email protected];;))
Aug 29 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:
RE-APPOINTS ARPIT SHAH AS MANAGING DIRECTOR
Source text: ID:nNSEbXnMqX
Further company coverage: REMP.NS
(([email protected];;))
June 20 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:
INCORPORATES SUBSIDIARY FOR CLINICAL TRIAL MATERIAL MANAGEMENT
Source text: ID:nNSEbjVg2k
Further company coverage: REMP.NS
(([email protected];;))
June 20 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:
INCORPORATES SUBSIDIARY FOR CLINICAL TRIAL MATERIAL MANAGEMENT
Source text: ID:nNSEbjVg2k
Further company coverage: REMP.NS
(([email protected];;))
Feb 7 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:
ACQUIRING MEMBERSHIP INTEREST OF 56.67% IN ESPEE GLOBAL HOLDINGS
APPROVED SETTING UP OF A BRANCH OFFICE IN DUBAI
ESPEE DEAL FOR $ 2.7 MILLION
Source text for Eikon: ID:nNSE5csCmR
Further company coverage: REMP.NS
(([email protected];))
Feb 7 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:
ACQUIRING MEMBERSHIP INTEREST OF 56.67% IN ESPEE GLOBAL HOLDINGS
APPROVED SETTING UP OF A BRANCH OFFICE IN DUBAI
ESPEE DEAL FOR $ 2.7 MILLION
Source text for Eikon: ID:nNSE5csCmR
Further company coverage: REMP.NS
(([email protected];))
Oct 19 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:
APPROVED TO SALE ENTIRE STAKE IT IN UNIT RATNATRIS PHARMACEUTICALS BY WAY OF SHARES SWAP
DISPOSAL/SALE BY WAY OF SHARES SWAP
Source text for Eikon: ID:nNSE19SdWv
Further company coverage: REMP.NS
(([email protected];))
Oct 19 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:
APPROVED TO SALE ENTIRE STAKE IT IN UNIT RATNATRIS PHARMACEUTICALS BY WAY OF SHARES SWAP
DISPOSAL/SALE BY WAY OF SHARES SWAP
Source text for Eikon: ID:nNSE19SdWv
Further company coverage: REMP.NS
(([email protected];))
Sept 15 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:
TO MAKE A STRATEGIC INVESTMENT IN ESPEE BIOPHARMA & FINECHEM LLC
INVESTMENT BY ACQUIRING AND/OR SUBSCRIBING TO MEMBERSHIP INTEREST OF 51% OR MORE STAKE IN INVESTEE COMPANY
Source text for Eikon: ID:nNSE5CWGZ6
Further company coverage: REMP.NS
(([email protected];))
Sept 15 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:
TO MAKE A STRATEGIC INVESTMENT IN ESPEE BIOPHARMA & FINECHEM LLC
INVESTMENT BY ACQUIRING AND/OR SUBSCRIBING TO MEMBERSHIP INTEREST OF 51% OR MORE STAKE IN INVESTEE COMPANY
Source text for Eikon: ID:nNSE5CWGZ6
Further company coverage: REMP.NS
(([email protected];))
Aug 4 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:
APPROVED IN PRINCIPLE TO INCORPORATE 2 SUBSIDIARIES AND 2 WHOLLY OWNED SUBSIDIARIES OUTSIDE INDIA
Source text for Eikon: ID:nNSE527SYr
Further company coverage: REMP.NS
(([email protected];;))
Aug 4 (Reuters) - Remus Pharmaceuticals Ltd REMP.NS:
APPROVED IN PRINCIPLE TO INCORPORATE 2 SUBSIDIARIES AND 2 WHOLLY OWNED SUBSIDIARIES OUTSIDE INDIA
Source text for Eikon: ID:nNSE527SYr
Further company coverage: REMP.NS
(([email protected];;))
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Remus Pharmaceutical do?
Remus Pharmaceuticals Limited is involved in marketing, distributing pharmaceutical formulations and APIs. It offers technical consultancy services to distributors and aims to build lasting relationships globally.
Who are the competitors of Remus Pharmaceutical?
Remus Pharmaceutical major competitors are Shree Ganesh Remed., Anlon Healthcare, Anuh Pharma, Bharat Parenterals, Kopran, Influx Healthtech, Amanta Healthcare. Market Cap of Remus Pharmaceutical is ₹871 Crs. While the median market cap of its peers are ₹805 Crs.
Is Remus Pharmaceutical financially stable compared to its competitors?
Remus Pharmaceutical seems to be less financially stable compared to its competitors. Altman Z score of Remus Pharmaceutical is 4.71 and is ranked 5 out of its 8 competitors.
Does Remus Pharmaceutical pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Remus Pharmaceutical latest dividend payout ratio is 3.04% and 3yr average dividend payout ratio is 3.3%
How has Remus Pharmaceutical allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Remus Pharmaceutical balance sheet?
Balance sheet of Remus Pharmaceutical is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Remus Pharmaceutical improving?
Yes, profit is increasing. The profit of Remus Pharmaceutical is ₹29.07 Crs for Mar 2025, ₹20.53 Crs for Mar 2024 and ₹8.5 Crs for Mar 2023
Is the debt of Remus Pharmaceutical increasing or decreasing?
Yes, The net debt of Remus Pharmaceutical is increasing. Latest net debt of Remus Pharmaceutical is ₹10.16 Crs as of Mar-26. This is greater than Mar-25 when it was ₹4.68 Crs.
Is Remus Pharmaceutical stock expensive?
There is insufficient historical data to gauge this. Latest PE of Remus Pharmaceutical is 23.56
Has the share price of Remus Pharmaceutical grown faster than its competition?
Remus Pharmaceutical has given lower returns compared to its competitors. Remus Pharmaceutical has grown at ~-20.5% over the last 1yrs while peers have grown at a median rate of 12.3%
Is the promoter bullish about Remus Pharmaceutical?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 70.95% and last quarter promoter holding is 70.91%.
Are mutual funds buying/selling Remus Pharmaceutical?
There is Insufficient data to gauge this.